CPRX - Citi starts Catalyst at buy cites rare disease drug portfolio
2024-03-14 15:09:19 ET
More on Catalyst Pharmaceuticals
- Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript
- Biotech And Pharma Diversification Pays Off
- Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch
- Catalyst announces US launch of Duchenne drug Agamree
- Catalyst Pharmaceuticals Non-GAAP EPS of $0.53 beats by $0.07, revenue of $110.57M beats by $4.65M